Zheng Li

Zheng Li

Auto-generated profile, based on publicly available information

Zheng Li

Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology, Shanghai, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
XLXiao Liu
Xiao Liu
JMJun Mi
Jun Mi
HQHaihong Qin
Haihong Qin
ZLZheng Li
Zheng Li
JCJingxiu Chai
Jingxiu Chai
JXJinhua Xu
Jinhua Xu

22 April 2025 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
JLJinran Lin
Jinran Lin
ZLZheng Li
Zheng Li
LSLinxia Shen
Linxia Shen
JLJui-Ming Lin
Jui-Ming Lin
KTKe Tao
Ke Tao
WWWenyu Wu
Wenyu Wu

7 March 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
YWYu Wang
Yu Wang
HYHuibin Yin
Huibin Yin
ZLZheng Li
Zheng Li
HWHao Wu
Hao Wu
QWQianhao Wang
Qianhao Wang
WLWei Li
Wei Li

30 May 2025 in Anais Brasileiros de Dermatologia (Versão em Português)
Verified
Journal Article
Open access
ZLZheng Li
Zheng Li
LSLinxia Shen
Linxia Shen
JLJui‐Ming Lin
Jui‐Ming Lin
KTKe Tao
Ke Tao
YMYing Miao
Ying Miao
WWWenyu Wu
Wenyu Wu

1 January 2026 in Dermatologic Therapy
Verified
Journal Article
Open access
ZLZheng Li
Zheng Li
YWYuemeng Wu
Yuemeng Wu
HWHao Wu
Hao Wu
YHYe He
Ye He
YWYu Wang
Yu Wang
CGChaoying Gu
Chaoying Gu
Background: Abrocitinib has shown significant efficacy and safety in clinical trials for moderate‐to‐severe atopic dermatitis (AD), but long‐term real‐world data are scarce. Objective: To assess the long‐term efficacy, predictors of response, and safety profiles associated with abrocitinib treatment in a real‐world setting. Methods: This prospective study enrolled 147 moderate‐to‐severe AD patients, and physician‐ and patient‐reported outcomes were evaluated at multiple time points. Results: Abrocitinib rapidly reduced Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA), Itch Numeric Rating Scale (Itch‐NRS), and body surface area (BSA) from Week 4 throughout Week 52, with 83.1% and 53.2% of patients achieving EASI‐75 and EASI‐90, respectively, at Week 52. Improvement was less pronounced in the head and neck compared to the trunk and limbs. Shorter disease duration (<   84 months) and the absence of allergic comorbidities predicted better long‐term response. Patients achieving EASI‐75 or EASI‐90 by Week 4 were more likely to maintain control at Week 52. Drug survival was 72.7% at Week 52. Adverse events (AEs) occurred in 61.9% of patients, with acneiform eruptions (19.7%) and gastrointestinal symptoms (17.7%) being most common within Week 12. After 12 weeks, hypercholesterolemia, abnormal liver function, and infections increased. Conclusion: Abrocitinib showed promising long‐term efficacy and safety in Chinese patients with moderate‐to‐severe AD, while consistent lab monitoring is required. Trial Registration: Chinese Registry of Clinical Trials: ChiCTR2200063195